STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM
News
August 29, 2025

Debunks myths surrounding obesity

Debunks myths surrounding obesity

According to the NHS, a BMI (Body Mass Index) between 25 and 30 is classified as overweight, and anything over 30 is considered obese. By this measure, it's estimated that a quarter of all UK adults are living with obesity.

Despite these facts, myths about obesity and its causes persist. A new survey from Yazen Health, providing a digital health care for medically assisted weight loss, reveals that over a third of Brits (37%) believe obesity is a lifestyle choice rather than a disease. They cite motivation (45%), laziness (43%), personal choice (33%), and genetics (33%) as the main barriers to maintaining a healthy weight.

We encourage patients to listen to expert advice and understand that obesity is a complex condition. Obesity is not just a matter of personal choice but a medical condition requiring proper care and treatment.

At Yazen, we are dedicated to providing the support and resources needed to address weight issues safely and effectively.

Let us help you on your journey to better health and well-being.

More news

WOD26: Data Reveals Persistent Shame & Stigma Around Obesity Treatment

Ahead of World Obesity Day on 4 March, Yazen is sharing new findings from internal patient data, revealing that shame and stigma remain major barriers to obesity care — even as effective medical treatments become more widely available.

UK firms eye GLP-1 benefits to cut sick leave and boost performance.

UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.

Yazen achieved record-breaking growth in 2025, doubling its revenue.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.